The early-stage human trial data of a COVID-19 vaccine developed by AstraZeneca and Oxford University reveals that it is safe and induces immune response, with mild side effects in some participants.<br />'' <br />''The preliminary results of the phase I/II trial, published in The Lancet journal, involving 1107 people show that the injection led to them making antibodies and T-cells that can fight coronavirus.<br />''Prof Andrew Pollard, from the Oxford research group said, the results are promising.<br />'' <br />''The study showed 90 percent of involved people developed neutralising antibodies after one dose.<br />'' <br />''Only ten people were given two doses and all of them produced neutralising antibodies.<br />'' <br />''Prof Sarah Gilbert, from the University of Oxford, UK, said there is still much work to be done but these early results hold promise.<br />'' <br />''The vaccine – called ChAdOx1 nCoV-19 – is being developed at unprecedented speed.<br />'' <br />''<span style="color: #222222;">It is made from a genetically engineered virus that causes the common cold in chimpanzees.</span><br />